Skip to content
Q-Line Biotech logo

Q-Line Biotech IPO

NSE SMEListedPharma & Healthcare
Check allotment status
Issue price
₹343
Listing price
₹452
+31.78%
Current price
₹488.3
+42.36%
Subscribed
102.49x
Issue size
₹251 Cr
Listed on
29 May 2026

IPO timeline

  1. Opens
    21 MayThu
  2. Closes
    25 MayMon
  3. Allotment
    26 MayTue
  4. Refunds
    27 MayWed
  5. Demat credit
    27 MayWed
  6. Listing
    29 MayFri

Issue details

Price band
₹326 – ₹343 per share
Issue size
₹251 Cr
Fresh issue
Not available
Offer for sale
Not available
Issue type
—
Face value
₹10 per share
Lot size
400 shares
Minimum investment
₹1,37,200
Listing on
NSE SME
Exchange code
QLINE-SM · QLINE

Lot size and investment

ApplicationLotsSharesAmount
Retail (Min)1400₹1,37,200
Retail (Max)1400₹1,37,200
HNI (Min)2800₹2,74,400

Allotment status

Registrar: Purva Sharegistry (India) Private Limited

The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).

Check allotment on Purva Sharegistry (India)
  1. 1Open the registrar's allotment page and select this IPO from the list.
  2. 2Enter your PAN, application number or DP / Client ID.
  3. 3Submit to see the number of shares allotted, if any.
Basis of allotment
26 May 2026
Refunds initiated
27 May 2026
Shares credited to demat
27 May 2026
Listing
29 May 2026

Grey market premium (GMP)

Updated 27 May 2026, 12:01 PM IST
Current GMP
₹108
+31.00%
Estimated listing price
₹451
Issue price ₹343
Highest
₹140
21 May
Lowest
₹42
18 May

GMP by day (₹ per share)

Day-wise GMP table
DateGMPPremiumEst. listing
27 May 2026₹108+31.00%₹451
26 May 2026₹99+29.00%₹442
25 May 2026₹126+37.00%₹469
23 May 2026₹130+38.00%₹473
22 May 2026₹120+35.00%₹463
21 May 2026₹140+41.00%₹483
20 May 2026₹110+32.00%₹453
19 May 2026₹69+20.00%₹412
18 May 2026₹42+12.00%₹385
Kostak rate
₹0

GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.

Subscription status

Updated 25 May 2026, 05:10 PM IST
Overall subscription
102.49x
Fully subscribed
  • QIB123.94x
  • NII (HNI)146.33x
  • Retail71.44x
  • Anchor1x
CategoryShares offeredShares bid forSubscribed
Qualified Institutional Buyers (QIB)11,88,00014,72,37,200123.94x
Non-Institutional Investors (NII)8,91,60013,04,66,800146.33x
Retail Individual Investors (RII)20,79,20014,85,32,80071.44x
Anchor Investors17,81,20017,81,2001x
Total41,58,80042,62,36,800102.49x
CompanyIssue sizeP/ERoNWPAT marginSubscribedListing gain
Q-Line Biotech
This IPO
₹251 Cr———102.49x+31.78%
Credent Connect N Care
SME · listed 20 Aug 2026
₹93.9 Cr18.6814.13%2.88%142.38x+90.00%
Pramodini Medicare
SME · listed 19 Aug 2026
₹69.04 Cr14.9732.69%27.90%3.66x+1.69%
Bio Medica Laboratories
SME · listed 29 May 2026
₹52 Cr13.4599.59%25.64%2.31x-20.00%
ABH Healthcare
SME · listed 1 Sep 2026
₹34.98 Cr20.6939.07%10.74%1.42x-2.94%
Avience Biomedicals
SME · listed 25 Jun 2026
₹30.24 Cr16.5649.89%15.86%385.4x+90.00%
Speciality Medicines
SME · listed 30 Mar 2026
₹29 Cr10.4928.30%14.77%2.19x0.00%

Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.

IPO objectives

How Q-Line Biotech plans to use the money raised, as stated in the offer document.

About Q-Line Biotech

Q-Line Biotech was incorporated in 2010 and is engaged in the business of developing, manufacturing, and supplying in-vitro diagnostic (IVD) products and medical diagnostic equipment. The company started with a focus on healthcare diagnostics and has gradually expanded its portfolio across clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, ELISA kits, rapid testing kits, and pathology equipment. It operates manufacturing facilities in Delhi and serves hospitals, diagnostic laboratories, and medical colleges across India through a wide distributor network. The company is promoted by Saurabh Garg along with Amita Garg and other promoter group members. Q-Line Biotech follows a business model focused on indigenous manufacturing, imports, distribution, and after-sales support for diagnostic instruments and consumables. The company emphasises affordable healthcare solutions under the “Make in India” initiative while investing in research, quality control, and technology-driven manufacturing to strengthen its position in the Indian diagnostic industry.

Strengths

  • Strong presence in the diagnostic and IVD products industry across India.
  • Wide product portfolio including biochemistry, molecular diagnostics, ELISA, and rapid test kits.
  • Focus on indigenous manufacturing under the “Make in India” initiative.
  • Experienced promoter leadership with healthcare industry expertise and nationwide distribution network.
  • Strong emphasis on R&D, quality standards, and ISO-certified manufacturing processes.

Risks

  • Business depends heavily on the healthcare and diagnostics sector demand cycle.
  • High competition from established multinational diagnostic and medical device companies.
  • Regulatory changes in medical devices and diagnostic products may impact operations.
  • Dependence on continuous innovation and new product approvals for growth.
  • Any disruption in raw material supply or distributor network can affect business performance.

Promoters and shareholding

Shares outstanding, pre-issue
96.77
Shares outstanding, post-issue
—

Registrar, lead managers and documents

Registrar

Purva Sharegistry (India) Private Limited

+91 22 2301 8261

support@purvashare.com

Q-Line Biotech IPO: common questions

1.When does the Q-Line Biotech IPO open and close?

The Q-Line Biotech IPO opens on 21 May 2026 and closes on 25 May 2026.

2.What is the price band of the Q-Line Biotech IPO?

The price band is ₹326 – ₹343 per share, with a lot size of 400 shares and a minimum investment of ₹1,37,200.

3.What is the size of the Q-Line Biotech IPO?

The issue size is ₹251 Cr.

4.What is the GMP of the Q-Line Biotech IPO?

The last reported grey market premium is ₹108 per share as of 27 May 2026, 12:01 PM IST. GMP is unofficial and changes frequently.

5.When is the Q-Line Biotech IPO allotment?

The basis of allotment is expected on 26 May 2026. Allotment status can be checked with the registrar, Purva Sharegistry (India) Private Limited.

6.When will the Q-Line Biotech IPO list?

The shares listed on 29 May 2026 on NSE SME.

7.How can my company launch an IPO like Q-Line Biotech?

Start with an IPO readiness assessment: eligibility for the NSE Emerge or BSE SME platform, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.

For business owners

Your company could be the next listing

Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.

  • Eligibility check against NSE Emerge, BSE SME and Main Board norms
  • Indicative valuation and issue size for your business
  • A clear timeline from readiness to listing day

Check if your business can list

Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.

Prefer to talk? Call +91 92130 20393